Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H29I2NO3 |
Molecular Weight | 645.3116 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3
InChI
InChIKey=IYIKLHRQXLHMJQ-UHFFFAOYSA-N
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
Molecular Formula | C25H29I2NO3 |
Molecular Weight | 645.3116 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/amiodarone.html | DOI: 10.1007/978-1-4613-2827-8_26
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/amiodarone.html | DOI: 10.1007/978-1-4613-2827-8_26
Amiodarone is an antiarrhythmic with mainly class III properties, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. In addition to blocking sodium channels, amiodarone blocks myocardial potassium channels, which contributes to slowing of conduction and prolongation of refractoriness. It is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. The most common adverse reactions (1-2%) leading to discontinuation of intravenous amiodarone therapy are hypotension, asystole/cardiac arrest/pulseless electrical activity, VT, and cardiogenic shock. Other important adverse reactions are, torsade de pointes (TdP), congestive heart failure, and liver function test abnormalities. Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation. There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly. Since amiodarone is a substrate for CYP3A and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4096733
Curator's Comment: The penetration of amiodarone into brain is poor.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094118 |
|||
Target ID: CHEMBL240 |
9.8 µM [IC50] | ||
Target ID: Voltage-gated T-type calcium channel (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1281221 |
|||
Target ID: Voltage-gated L-type calcium channel (guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1281221 |
|||
Target ID: CHEMBL2364675 |
|||
Target ID: CHEMBL3721 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PACERONE Approved UseAmiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy. Launch Date1998 |
|||
Primary | PACERONE Approved UseAmiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [ see Dosage and Administration (2) Launch Date1998 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2920 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
1.25 mg/kg single, intravenous dose: 1.25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7140 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13660 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
1.25 mg/kg single, intravenous dose: 1.25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DESETHYLAMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
23.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DESETHYLAMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
41.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DESETHYLAMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6851030/ |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
1.25 mg/kg single, intravenous dose: 1.25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DESETHYLAMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
14.2 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21052689/ |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DESETHYLAMIODARONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.62 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6851030/ |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMIODARONE serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.023% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3242577/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMIODARONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 15 uM] | yes (co-administration study) Comment: reversible inhibition; The area under the plasma concentration-time curve (AUC) of metoprolol increased from 767 before to 1,387 ug * hours/L after the amiodarone loading dose |
|||
yes [IC50 5.48 uM] | ||||
yes [IC50 >50 uM] | yes (co-administration study) Comment: reversible inhibition; After treatment with 3 g amiodarone (phase I), this parameter (AUC of lidocaine) increased to 135.3 ± 34.6 (p = 0.016), whereas the AUC of MEGEX decreased from 19.2 ± 6.5 to 15.8 ± 8.3 μg/min/ml (p = 0.04). |
|||
yes [IC50 >50 uM] | yes (co-administration study) Comment: reversible inhibition; The mean warfarin AUC during the amiodarone regimen increased to 200% of the control value of anticoagulant alone, from 624 ± 59 Rg/ml-hr to 1249 ± 115 p,g/ml-hr, a significant difference |
|||
yes [IC50 >50 uM] | yes (co-administration study) Comment: reversible inhibition; The mean warfarin AUC during the amiodarone regimen increased to 200% of the control value of anticoagulant alone, from 624 ± 59 Rg/ml-hr to 1249 ± 115 p,g/ml-hr, a significant difference |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Sources: https://pubmed.ncbi.nlm.nih.gov/11038157/ |
|||
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Sources: https://pubmed.ncbi.nlm.nih.gov/11038157/ |
|||
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Sources: https://pubmed.ncbi.nlm.nih.gov/11038157/ |
|||
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Page: 9.0 |
|||
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Sources: https://pubmed.ncbi.nlm.nih.gov/11038157/ |
|||
yes | likely (co-administration study) Comment: CYP450 inhibitors: grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors: increased exposure of amiodarone. Avoid concomitant use. CYP450 inducers (St. John's Wort): reduced amiodarone serum levels Page: 9.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Ocular toxicology. | 1994 Dec |
|
Bilateral anterior ischaemic optic neuropathy following amiodarone. | 1998 |
|
[Severe flecainide acetate poisoning. Apropos of a case]. | 1999 Feb |
|
[Amiodarone-induced bilateral optic atrophy--a case report]. | 1999 Jun |
|
Early proarrhythmia during intravenous amiodarone treatment. | 1999 Jun |
|
Acetazolamide-responsive periodic ataxia induced by amiodarone. | 1999 Mar |
|
Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. | 1999 Mar |
|
Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials. | 1999 Mar 11 |
|
Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. | 1999 Oct |
|
Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. | 2000 Apr |
|
Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). | 2000 Apr |
|
[Amiodarone-associated optic neuropathy: an independent syndrome? Three patients with bilateral optic neuropathy]. | 2000 Sep |
|
Amiodarone-related optic neuropathy. | 2000 Sep-Oct |
|
The effects of amiodarone on the thyroid. | 2001 Apr |
|
Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension culture. | 2001 Feb |
|
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. | 2001 Feb |
|
Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. | 2001 Feb |
|
Thyroid hormone and the cardiovascular system. | 2001 Feb 15 |
|
Impressive amelioration of clinical (NYHA class) and echocardiographic parameters in heart failure patients treated with amiodarone and carvedilol. | 2001 Jan |
|
Development of heart failure in bradycardic sick sinus syndrome. | 2001 Jan |
|
The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation. | 2001 Jan |
|
Dofetilide: a new class III antiarrhythmic agent. | 2001 Jan |
|
Amiodarone-induced hyperthyroidism. | 2001 Jan 22 |
|
The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. | 2001 Mar |
|
[Hyperthyroidism and heart]. | 2001 Mar 15 |
|
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. | 2001 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/amiodarone.html
Intravenous: Initial dose: 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen:
-Loading infusions: 150 mg over the first 10 minutes (15 mg/min), followed by 360 mg over the next 6 hours (1 mg/min)
-Maintenance infusion: 540 mg over the remaining 18 hours (0.5 mg/min)
Maintenance dose: After the first 24 hours, continue the maintenance infusion rate of 0.5 mg/min; may increase infusion rate to achieve effective arrhythmia suppression.
-Supplemental infusions: 150 mg over 10 minutes (15 mg/min) for breakthrough episodes of ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia(VT)
Maximum dose: Initial infusion rate: 30 mg/min
Oral: Loading dose: 800 to 1600 mg orally per day for 1 to 3 weeks (occasionally longer) until adequate arrhythmia control is achieved or if side effects become prominent, then switch to adjustment dose
Adjustment dose: 600 to 800 mg orally per day for 1 month, then switch to maintenance dose
Maintenance dose: 400 mg orally per day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8156930
At concentrations ranging from 75-200 uM, amiodarone induced a significant and dose-dependent release of 51Cr in FRTL-5 cells. In the same molar concentrations, amiodarone was also cytotoxic in CHO cells. In hTF, the release of 51Cr produced by amiodarone occurred at a lower concentration (37.5 vs. 75 uM) and was significantly greater than that in FRTL-5 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:56:58 GMT 2025
by
admin
on
Mon Mar 31 17:56:58 GMT 2025
|
Record UNII |
N3RQ532IUT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
UCSF-FDA TRANSPORTAL |
AMIODARONE
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
WHO-VATC |
QC01BD01
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
FDA ORPHAN DRUG |
70292
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
NDF-RT |
N0000175426
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.2
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
LIVERTOX |
NBK548109
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
||
|
WHO-ATC |
C01BD01
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000089825
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
DTXSID7022592
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
2566
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
N0000182141
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
D000638
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
DB01118
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
N3RQ532IUT
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
703
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | RxNorm | ||
|
217-772-1
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
AMIODARONE
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
176
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
N0000182138
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | Cytochrome P450 1A2 Inhibitors [MoA] | ||
|
1951-25-3
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
SUB05451MIG
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
2157
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
C62002
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
N0000185503
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
N3RQ532IUT
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
2663
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
CHEMBL633
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
N0000185504
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | Cytochrome P450 2C9 Inhibitors [MoA] | ||
|
m1748
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000182137
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
Amiodarone
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY | |||
|
2012
Created by
admin on Mon Mar 31 17:56:58 GMT 2025 , Edited by admin on Mon Mar 31 17:56:58 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
ACTIVE AT HIGH CONCENTRATIONS; AMIODARONE CONCENTRATES IN THE LIVER
MAJOR
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE -> PARENT |
BILE
|
||
|
METABOLITE -> PARENT |
MAJOR
BILE
|
||
|
METABOLITE -> PARENT |
BILE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||